2026-526494-42-00Not yet recruitingPhase 2
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients with Gastric Cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 5 Jun 2026
Brief summary (registry, in English)
1) To assess the accuracy of 18F-FAPI-74 PET/CT in detection of local lymph node or distant metastasis on patient level in patients with primary GC 2) To assess the accuracy of 18F-FAPI-74 PET/CT in assessing the neoadjuvant therapy response among primary GC patients undergoing surgery
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 10 Apr 2026
- Start date
- 1 Jun 2026
- Lead sponsor
- Varsinais-Suomen hyvinvointialue
- Diseases
- Gastric and esophageal cancer
- EU CT number
- 2026-526494-42-00
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 80
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with suspected primary or recurrent gastric cancer. It tests a PET/CT scan with 18F-FAPI-74.
- Age
- 18-85 years
- Sex
- Men and women can join.
- Disease stage
- Suspected primary or recurrent gastric cancer.
Main reasons for not taking part
- Pregnant or breast-feeding women cannot join
- Children, disabled people and prisoners cannot join
- People who cannot understand the purpose of the study cannot join
- People with medical conditions that prevent whole-body PET/CT imaging cannot join
Read by machine on 9 Nov 2026.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other illness
- Medical conditions prohibiting whole-body PET/CT imaging
Other
- Vulnerable study subjects such as described in Finnish law clinical studies (disabled, children, pregnant or breast-feeding women, prisoners) will not be included
- Study subject cannot understand the purpose of the purpose of the study
Who the study is looking for
- Suspected primary or recurrent gastric cancer
- Subjects must be male or female aged 18-85 years
- WHO performance score 0-2
- Subjects must be able and willing to give written informed consent and to comply with the requirements of the study protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Varsinais-Suomen hyvinvointialue | Turku | Finland | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.